medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2007, Number 2

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2007; 20 (2)

Analysis of treatment after hospital discharge in patients with chronic obstructive pulmonary disease

Flores MS, Álvarez VBC, Ruiz AJ, Prado ME, Gil NMV

Language: Spanish
References: 16
Page: 113-118
PDF size: 79.38 Kb.


ABSTRACT

Objective: To evaluate the pharmacologic and non pharmacologic treatment for patients with chronic obstructive pulmonary disease (COPD), after discharge from a university hospital.
Methods: We conducted a retrospective study of patients with COPD admitted to a University Hospital between January 2005 and June 2006. Medical records were retrospectively reviewed after hospital discharge and critically evaluated according to international recommendations.
Results: There were four hundred and seven admissions for COPD; 75 were not included due to lack of sufficient information or death of the patients; three hundred and thirty two patients were evaluated, 86% male, mean age 69 ± 10.3 years. At discharge, the following drugs were prescribed: antimuscarinic 82.2%, short-acting b2-agonists 61.1%, long-acting b2-agonists 51.9%, systemic steroids 51%, inhaled steroids 39.3%; mucolytic medications 37%, methylxanthines 0.9%; non pharmaceutical treatments ‹ 30%.
Conclusion: This retrospective observational study confirms a substantial variability in COPD treatment after hospital discharge. Due to the high prevalence of COPD and the long duration of treatment, important clinical and economic consequences are derived.


REFERENCES

  1. Price D, Duerden M. Chronic obstructive pulmonary disease. BMJ 2003;326:1046-1047.

  2. Vineis P, Airoldi L, Veglia P, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 2005;330:277-282.

  3. Devereux G. ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors. BMJ 2006;332:1142-1144.

  4. Pauwels R. Global initiative for chronic obstructive lung diseases (GOLD): time to act. Eur Respir J 2001;18: 901-902.

  5. Mayor S. New guidelines aim to improve management of COPD. BMJ 2004; 328:1336.

  6. Sansores MR, Ramírez-Venegas A. Enfermedad pulmonar obstructiva crónica y la celebración de su primer Día Mundial (editorial). Rev Inst Nal Enf Resp Mex 2002;15:199-200.

  7. Escarrabill J. Costes sanitarios de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 2003;39: 435-436.

  8. Navarro RF. Efecto de las combinaciones salbutamol-ipratropio y salbutamol-tiotropio inhalados y teofilina vía oral en pacientes con EPOC. Análisis de costo/efectividad. Rev Inst Nal Enf Res Mex 2006: 19:122-126.

  9. Pawles RA, Buits AS, Calverley PMA, Jenkins CR, Hurd SS (GOLD Scientific Committee). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Update 2003. Disponible en: www.copdgold.com

  10. INER, SMNyCT. Guías para el Diagnóstico y el Tratamiento de la Enfermedad Pulmonar Obstructiva Crónica: Edición especial. México: INER, SMNyCT;2003.p.50.

  11. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. NICE guideline nº 12. Thorax 2004;59 Suppl 1:1-232.

  12. Rudolf M. The reality of drug use in COPD: the European perspective. Chest 2000;117(2 Suppl):29-32.

  13. Miravitlles M, Mayordomo M, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL, on behalf of the EOLO Group. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med 1999;93:173-179.

  14. Miravitlles M, Murio C, Guerrero T, Segú JL. Tratamiento de la bronquitis crónica y la EPOC en atención primaria. Arch Bronconeumol 1999;35:173-178.

  15. Poole PJ, Black PN. Agentes mucolíticos para la bronquitis crónica o la enfermedad pulmonar obstructiva crónica (revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 1. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com (traducida por The Cochrane Library 2007 Issue 1. Chichester, UK: John Wiley & Sons, Ltd).

  16. Prilosec®:omeprazole US. Food and Drug Administration (FDA). http://www.fda.gov/cder/foi/label/2006/019810s083lbl.pdf




2020     |     www.medigraphic.com